Praxis precision medicines provides corporate update and reports third quarter 2023 financial results

Essential3 study initiated, with over 600 patients engaged in pre-recruitment observational study elsunersen embrave study final dose completed, praxis seeking fda advice on advancing development cash of $101.1 million  as of september 30, 2023 supports runway into q1 2025 boston, nov. 07, 2023 (globe newswire) -- praxis precision medicines, inc. (nasdaq: prax), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (cns) disorders characterized by neuronal excitation-inhibition imbalance, today provided a corporate update and reported financial results for the third quarter 2023. “this quarter was momentous for praxis as we began our first phase 3 studies in ulixacaltamide for essential tremor,” said marcio souza, president and chief executive officer of praxis.
PRAX Ratings Summary
PRAX Quant Ranking